BCYC insider files Form 144 to sell 543 Nasdaq shares
Rhea-AI Filing Summary
Bicycle Therapeutics plc (BCYC) filed a Form 144 notifying a proposed sale of 543 shares of Common Stock through Stifel Nicolaus & Company Inc with an aggregate market value of $4,563. The filing lists the securities as to be sold on or about 10/02/2025 on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 (1,000 units) and 10/03/2025 (593 units). Prior reported sales by the same person in the past three months total 304 shares for gross proceeds of $2,191.
Positive
- Planned sale disclosed via Form 144 showing regulatory compliance
- Broker-dealer execution identified as Stifel Nicolaus & Company Inc
Negative
- Recent insider sales of 304 shares in July 2025 totaling $2,191
- Shares derived from RSUs issued on 10/02/2025 and 10/03/2025 are being sold soon after acquisition
Insights
Form 144 notifies a small, rule-compliant insider sale via broker on Nasdaq.
The filing shows a proposed sale of 543 shares with an aggregate market value of $4,563 through Stifel Nicolaus, indicating the filer intends to use a broker-dealer to execute the transaction.
The securities were issued as Restricted Stock Units on 10/02/2025 and 10/03/2025, and the filer disclosed prior open-market sales of 304 shares in July 2025 totaling $2,191, which are reported for aggregation under Rule 144.